FindTrial
Sign In

ROSY-S: Rollover Study for Participants Who have Completed a Previous Study with Anifrolumab (Saphnelo) and Are Assessed by the Investigator to Clinically Benefit From Continued Treatment

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2026-526419-13-00
Enrollment
72
Registered
2026-10-20
Start date
Unknown
Completion date
Unknown
Last updated
2026-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Sclerosis Cutaneous Lupus Erythematosus Myopathies Systemic Lupus Erythematosus

Brief summary

Safety will be evaluated by monitoring and assessing SAEs and non-serious AEs a reported throughout the study and until 12 weeks after the last dose of anifrolumab

Interventions

DRUGSaphnelo 300 mg concentrate for solution for infusion
DRUGSaphnelo 120 mg solution for injection in pre-filled syringe

Sponsors

AstraZeneca AB
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
0 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Safety will be evaluated by monitoring and assessing SAEs and non-serious AEs a reported throughout the study and until 12 weeks after the last dose of anifrolumab—

Outcome results

None listed

Source: EU CTIS · Data processed: Oct 22, 2026